Board of Directors


  • Cynthia Lander, PhD, Chairman
    • Corp development strategy, device marketing/partnering, general management
    • CEO/Chairman Moerae Matrix;
    • Partner, Nascent Enterprises;
    • Managing DirCynapseConsul8ng;
    • SVP, PublicisGroupe
    • Rockefeller, Yale, NYU, Juilliard
  • Geoff Davis, MD
    • Biopharmaceuticals, protein therapeutics, oncology
    • CEO/Founder/Director, Angelica Therapeutics; CSO/Founder, Abgenix;
    • Faculty, UCSF; PhD UC Berkeley
  • Jay Skyler, MD
    • Metabolism/inflammation/autoimmunity
    • University of Miami; Director, Amylin Pharmaceuticals
  • Scott Paseltiner, JD
    • Finance, private equity, executive coaching and consulting
    • Director • Founder/Director 1st Variable Rate Fund of Calvert Group Mutual Funds;
    • Lead Investor/Director, Global Patent Holdings/Distributed Bit
  • Ramy Mahmoud, MD
    • COO, OptiNose
    • 14 years JNJ, Global Management Board and CMO, Ethicon
    • 10 years US Army, battalion/flight surgeon, Head, Dept of Epidemiology at Walter Reed
  • Tony Dimun, CPA
    • Medical device expertise, business development, finance, venture investorFounder, Nascent Enterprises; EVP Vital Signs (sold to GE Healthcare ~$900M)
    • Director of 5 public medical device companies
    • NJ Biomaterials Institute, Ernst & Young
  • Jeffrey O’Donnell, Sr.
    • More than20 years of Board and Chief Executive experience running emerging medical device firms.
    • President and CEO of Trice Medical
    • Previously President & CEO Embrella Cardiovascular (sold to Edwards Life Sciences); President and CEO of PhotoMedex (NASDAQ: PHMD); President and CEO of Cardiovascular Dynamics; President and CEO of Kensey Nash Corporation (NASDAQ: KNSY)
    • Previous senior positions with Boston Scientific Corporation, Guidant Corporation, Johnson & Johnson’s Orthopedic Division.
    • Previous director for Cardiac Science (7 yrs.) and Endologix (12 yrs.); currently on the Board of BioSig Technologies; Chairman of the Board of Mela Sciences (NASDAQ: MELA).